511. Deputy Ken O'Flynn asked the Minister for Health whether the health technology assessments conducted in respect of tirzepatide included modelling of downstream healthcare cost offsets arising from reductions in incidence of type 2 diabetes; cardiovascular events; hospital admissions; and obesity-related complications; and to provide the percentage reductions assumed in each case within the base-case analysis. [15812/26]

Summary

511. Deputy Ken O'Flynn asked the Minister for Health whether the health technology assessments conducted in respect of tirzepatide included modelling of downstream healthcare cost offsets arising from reductions in incidence of type 2 diabetes; cardiovascular events; hospital admissions; and obesity-related complications; and to provide the percentage reductions assumed in each case within the base-case analysis. [15812/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 26 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.